Abstract
T-cell therapy–related acute lymphoblastic leukemia (T-t-ALL) is a rare condition associated with previous cytotoxic therapy for another disease. Here we report T-t-ALL with inv(11) (q21q23), which involves KMT2A and MAML2, a transcriptional coactivator of NOTCH proteins, that occurred after chemotherapy for Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. This case describes the youngest patient with T-t-ALL harboring inv(11)(q21q23) and is the first independent report following an initial series also occurring in children. Our results lend further support to the observation that the KMT2A-MAML2 fusion gene resulting from inv(11)(q21q23) is likely a recurrent cytogenetic abnormality in T-t-ALL and appears to be associated with pediatric cases.
Original language | English (US) |
---|---|
Pages (from-to) | E258-E261 |
Journal | Journal of pediatric hematology/oncology |
Volume | 42 |
Issue number | 4 |
DOIs | |
State | Published - May 1 2020 |
Keywords
- Inv(11)(q21q23)
- KMT2A
- MAML2
- T-cell ALL
- Therapy-related acute lymphoblastic leukemia
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology